Nav1.5 Ser571 Phosphorylation Drives Cardiac Aging Phenotypes

Study Background and Research Question

Aging is the leading independent risk factor for chronic heart failure and cardiac dysfunction in individuals over 65, with growing public health implications as the elderly population expands. Despite extensive research, the molecular mechanisms linking aging to cardiac diastolic dysfunction and increased arrhythmia susceptibility remain incompletely understood. Recent evidence implicates changes in cardiomyocyte ion channel dynamics—particularly the late sodium current (INa,L)—in age-related electrical and mechanical remodeling of the heart. The reference study, published in Am J Physiol Heart Circ Physiol, directly investigates the role of Nav1.5 channel phosphorylation at Ser571 in modulating INa,L and the subsequent development of aging-associated cardiac phenotypes.

Key Innovation from the Reference Study

The major innovation of this research lies in its direct genetic dissection of the impact of Nav1.5 Ser571 phosphorylation on cardiac function during aging. By utilizing engineered mouse models with either phosphomimetic (gain-of-function, GoF) or phosphoablated (loss-of-function, LoF) mutations at this site, the study isolates the causal influence of Ser571-mediated INa,L augmentation. This approach moves beyond correlative observations and establishes a mechanistic link between a specific post-translational modification and the progression of age-related cardiac electrical and mechanical dysfunctions. The study also demonstrates that pharmacological inhibition of INa,L can reverse certain aging-associated defects, highlighting actionable targets for arrhythmia prevention research.

Methods and Experimental Design Insights

The investigators employed a multi-pronged experimental design encompassing in vivo, ex vivo, and single-cell analyses in male and female C57Bl/6 mice. Three groups were compared: wild-type (WT), Nav1.5-Ser571 phosphomimetic (GoF), and Nav1.5-Ser571 phosphoablated (LoF) animals. Key methodological highlights include:

• Electrocardiographic (ECG) assessments for QT interval duration and arrhythmia susceptibility
• Echocardiographic and hemodynamic measurements to evaluate diastolic left ventricular filling
• Patch-clamp electrophysiology to quantify INa,L and action potential duration in isolated ventricular myocytes
• Calcium imaging and sarcomere shortening assays for contractile and relaxation kinetics
• Pharmacological late sodium current inhibition to test reversibility of aging-associated defects

These complementary approaches enable robust testing of both molecular mechanisms and functional outcomes, with an emphasis on translational relevance to in vitro cardiac electrophysiology and ventricular myocyte sodium current inhibition studies.

Core Findings and Why They Matter

The central findings, as detailed in the reference study, are as follows:

• Aging wild-type mice exhibit a ~60% increase in INa,L and a ~50% prolongation of action potential duration (APD90) in ventricular myocytes compared to young controls.
• QT interval prolongation and impaired diastolic left ventricular filling develop in WT mice by 18 months, recapitulating human aging myopathy features. These defects are reversed by INa,L inhibition.
• Phosphomimetic (GoF) mutants—mimicking constitutive Ser571 phosphorylation—develop delayed repolarization and diastolic dysfunction prematurely (as early as 5 months), with further deterioration in old age.
• Phosphoablated (LoF) Nav1.5 mutants are protected from age-associated electrical and mechanical dysfunctions, with minimal changes observed even at advanced ages.
• Delayed decay of Ca²⁺ transients and impaired myocyte relaxation are directly tied to increased INa,L, confirming the role of altered sodium channel phosphorylation in contractile reserve loss.

Collectively, these results demonstrate that Nav1.5 Ser571 phosphorylation is both necessary and sufficient to drive aging-like phenotypes in the myocardium by increasing late sodium current. This mechanistic insight not only clarifies the molecular etiology of age-related cardiac decline but also pinpoints the late sodium current as a rational intervention target for arrhythmia prevention and diastolic dysfunction studies.

Comparison with Existing Internal Articles

Several recent articles reinforce and contextualize these findings:

• Nav1.5 Ser571 Phosphorylation Links Aging to Cardiac Dysfunction provides a complementary overview of the molecular and electrophysiological impacts of Ser571 modification, highlighting the translational significance for researchers investigating arrhythmic risk in aged populations.
• GS967: Advanced Cardiac Late Sodium Current Inhibitor in Research discusses the practical use of selective late sodium current blockers such as GS967 in both in vitro and translational experimental workflows, emphasizing the importance of precise pharmacological tools to validate genetic findings in arrhythmia prevention research.
• Nav1.5 Ser571 Phosphorylation Drives Age-Related Cardiac Dysfunction further details the link between specific sodium channel post-translational modifications and the pathogenesis of diastolic dysfunction in aging, in alignment with the present study’s core conclusions.

These resources collectively underscore the emerging consensus around late sodium current modulation as a mechanistic and therapeutic focus in cardiac aging research.

Limitations and Transferability

While the use of genetically engineered mouse models provides direct evidence for the role of Nav1.5 Ser571 phosphorylation, certain limitations should be considered:

• Mouse cardiac physiology differs from that of humans, particularly regarding heart rate, action potential profiles, and sodium channel isoform expression. Direct translation to human cardiac aging requires further validation.
• The study primarily addresses the molecular and electrophysiological basis of diastolic dysfunction and arrhythmogenesis, but does not fully explore structural cardiac remodeling or comorbidities common in elderly patients.
• Pharmacological inhibition of INa,L in the study context reverses electrical defects, but potential off-target effects or long-term safety in human settings remain unaddressed.

Despite these caveats, the findings provide a robust foundation for further translational work and for the design of in vitro cardiac electrophysiology experiments targeting late sodium current modulation.

Protocol Parameters

• Animal model selection: Employ aged wild-type and genetically modified mice (phosphomimetic or phosphoablated Nav1.5 Ser571) for in vivo or ex vivo studies of late sodium current and cardiac function.
• INa,L measurement: Use whole-cell patch-clamp recordings in isolated ventricular myocytes to quantify late sodium current amplitudes and action potential duration at 90% repolarization (APD90).
• Pharmacological intervention: Apply selective cardiac late sodium current inhibitors during in vitro or in vivo protocols to assess reversibility of delayed repolarization and diastolic dysfunction phenotypes.
• Functional assays: Combine ECG, echocardiography, and calcium transient imaging to evaluate both electrical and contractile phenotypes in response to genetic or pharmacological manipulations.
• Data interpretation: Compare findings across age groups and genotypes to isolate the impact of Ser571 phosphorylation and INa,L augmentation on cardiac function.

Research Support Resources

For researchers seeking to model or modulate the late sodium current in cardiac electrophysiology or arrhythmia prevention research, GS967 (SKU B5850) is a potent and selective inhibitor of the cardiac late sodium current. According to the product information, GS967 exhibits submicromolar IC₅₀ values in ventricular myocytes and isolated hearts, making it highly suitable for in vitro workflows and ischemia-induced arrhythmia studies. When used alongside genetic models or for pharmacological validation, GS967 can help dissect the role of late sodium current in aging-related cardiac dysfunction. For more detailed protocols and troubleshooting insights, see this workflow-focused article. GS967 is supplied by APExBIO for research use only; consult technical documentation for storage and solvent compatibility.